IMpassion130, a phase III multicenter, randomized, double-blind, placebo-controlled trial in metastatic triple-negative breast cancer patients showed that high CD8+ TILs expression was significantly associated with improvements in OS and PFS [19]. The gene discussed is CD8A; the disease is triple-negative breast carcinoma.